APVO-451

N/A

Report date: 2026/03/19 17:03:50

Base Information

Drug NameAPVO-451
Drug Alias NameAPVO-451APVO451
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-NECTIN4Anti-CD3Anti-CD40
TargetsNectin-4T cell surface glycoprotein CD3Tumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsBreast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAptevo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAptevo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsBreast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A